Emergent (EBS) initiates a phase I study evaluating EBS-UFV-001, the company’s investigational universal influenza vaccine candidate.
Emergent (EBS) initiates a phase I study evaluating EBS-UFV-001, the company’s investigational universal influenza vaccine candidate.